NuGen Medical Devices Inc.
NGMD.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 205.89% | 197.06% | 199.06% | 307.87% | 373.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.89% | 197.06% | 199.06% | 307.87% | 373.94% |
| Cost of Revenue | 190.01% | 181.61% | 188.28% | 422.18% | 400.38% |
| Gross Profit | 222.50% | 213.50% | 210.07% | 226.96% | 350.71% |
| SG&A Expenses | -21.96% | -41.07% | -33.93% | -5.84% | 8.69% |
| Depreciation & Amortization | -7.08% | -10.37% | -7.91% | -18.12% | -8.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.03% | -33.65% | -27.38% | -2.69% | 8.86% |
| Operating Income | 26.91% | 44.04% | 36.69% | 10.67% | -4.53% |
| Income Before Tax | 57.59% | 79.11% | 44.31% | 3.79% | -1.60% |
| Income Tax Expenses | -43.75% | -68.67% | -79.52% | 274.65% | 190.91% |
| Earnings from Continuing Operations | 57.54% | 79.07% | 44.44% | 3.48% | -1.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.54% | 79.07% | 44.44% | 3.48% | -1.82% |
| EBIT | 26.91% | 44.04% | 36.69% | 10.67% | -4.53% |
| EBITDA | 30.35% | 47.74% | 39.77% | 9.98% | -6.68% |
| EPS Basic | 61.75% | 81.49% | 57.31% | 38.70% | 41.72% |
| Normalized Basic EPS | 49.17% | 70.48% | 48.12% | 40.39% | 42.54% |
| EPS Diluted | 61.75% | 81.49% | 57.31% | 38.70% | 41.72% |
| Normalized Diluted EPS | 49.17% | 70.48% | 48.12% | 40.39% | 42.54% |
| Average Basic Shares Outstanding | 10.65% | 16.77% | 28.01% | 50.32% | 74.47% |
| Average Diluted Shares Outstanding | 10.65% | 16.77% | 28.01% | 50.32% | 74.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |